Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.

De Souza, C A

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. [electronic resource] - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas Jul 2000 - 791-8 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

0100-879X

10.1590/s0100-879x2000000700009 doi


Adolescent
Adult
Amifostine--adverse effects
Antineoplastic Agents, Alkylating--administration & dosage
Cyclophosphamide--administration & dosage
Cytoprotection--drug effects
Feasibility Studies
Female
Humans
Lymphoma, Non-Hodgkin--drug therapy
Male
Middle Aged
Radiation-Protective Agents--adverse effects
Statistics, Nonparametric
Treatment Outcome